A new antiproliferative drug for exudative age-related macular degeneration
https://doi.org/10.34215/1609-1175-2022-3-91-95
Abstract
Age-related macular degeneration (AMD) is one of the major reasons that cause irreversible vision loss among older people. Over the past two decades, vascular endothelial growth factor (anti-VEGF) inhibitors have been successfully used in the treatment of AMD. In this article, we study a new antivasoproliferative agent brolucizumab for the treatment of exudative AMD forms. The drug has demonstrated its high effectiveness in terms of a more rapid onset of therapeutic effect and the resolution of intraretinal and subretinal exudation.
About the Authors
D. A. Rukina
Eye Center
Russian Federation
Russian Federation
Vladivostok
Ya. F. Pestryakova
Eye Center
Russian Federation
Russian Federation
Chief of Eye Center,
44, Partizansky Ave., Vladivostok, 690106
O. V. Miroshnichenko
Far Eastern Federal University
Russian Federation
Russian Federation
Vladivostok
S. O. Ustyugova
Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
References
1. Wang D, Jiang Y, He M, Scheetz J, Wang W. Disparities in the Global Burden of Age-Related Macular Degeneration: An Analysis of Trends from 1990 to 2015. Curr Eye Res. 2019;44(6):657–63. doi: 10.1080/02713683.2019.1576907
2. Oganezova JG. A new drug for treatment and prophylaxis of age-related macular degeneration. Russian Journal of Clinical Ophthalmology. 2013;14(3):130– 5 (In Russ.)
3. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):106–16. doi: 10.1016/S2214-109X(13)70145-1
4. Budzinskaya MV, Pluhova AA. Prospects of antiangiogenic therapy in retinal diseases. Ophthalmology. 2021;18(3S):638–45 (In Russ.)
5. Koroleva IA, Gvetadze AA, Romanova TB. Pharmacotherapy of AMD: overview of new trends. Clin. Ophthalmol. 2019;2:105–9. URL: https://www.rmj.ru/articles/oftalmologiya/Farmakoterapiya_VMD_obzor_novyh_tendenciy/#ixzz7NfohCUNz (In Russ.)] doi: 10.32364/2311-7729-2019-19-2-105-109.
6. Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A. Brolucizumab: a newly developed anti-VEGF molecule for the treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica, 2021, 244:93–101. doi: 10.1159/000513048
7. Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberg A. Brolucizumab versus Aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. American Academy of Ophthalmology. 2017;3:1–9. doi: 10/2016/j.ophtha.2017.03.057
8. Hussan RM, Ntal A, Yanussi NA, Patel KH, Huo S. Brolucizumab for persistant macular fluid in neovascular age-related macular degeneration after prior anti-VEGF tretments. Therapeutic Advances in Ophthalmology. 2021;13:1–10. doi: 10.1177/25158414211055964
9. Haensli C, Pfister IB, Garweg JG. Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. J. Clin. Med. 2021;10:2666. doi: 10.3390/jcm10122666
10. Fukuda Y, Sakurada Y, Matsubara M, Hasebe Y, Sugiyama A, Kikushima W. Comparison of outcomes between 3 monthly Brolucizumab and Aflibercept injections for Polypoidal Choroidal Vasculopathy. Biomedicines. 2021;9:1164. doi: 10.3390/biomedicines9091164
11. Montesel A, Bucolo C, Sallo FB, Eandi CM. Short-term efficacy and safety outcomes of Brolucizumab in the real-life clinical practice. Frontiers in Pharmacology. 2021;12. doi: 10.3389/fphar2021.720345
12. Baumal CR, Spaide RF, Vajzomic L, Bailey Freund K, Walter SD, John V, Rich R, Chaudhry N, Lakhanpal RR. Retinal Vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab. Ophthalmology. 2020;127(10):1345–59. doi: 10.1016/j.ophtha.2020.04.017
Review
For citations:
Rukina D.A., Pestryakova Ya.F., Miroshnichenko O.V., Ustyugova S.O. A new antiproliferative drug for exudative age-related macular degeneration. Pacific Medical Journal. 2022;(3):91-95. (In Russ.) https://doi.org/10.34215/1609-1175-2022-3-91-95
Views:
797
Email this article 